NEW YORK – Helaina, a biotechnology company that produces breast milk proteins, launched a human lactoferrin equivalent ingredient called effera.

The company said its precision fermentation process may replicate an equivalent protein to the lactoferrin found in human colostrum and maternal milk.  

Helaina also shared that it ran a clinical study that was both randomized and double-blind controlled to measure the body’s responses to its effera product.

It found participants taking bovine lactoferrin produced antibodies against the protein, suggesting an immunogenic response against bovine lactoferrin, the company reported. It also found participants taking effera, at both a high and low dose, produced no antibodies against the protein, suggesting better tolerability of the ingredient.

“We are starting to see with real clinical evidence and science-backed research that human proteins can outperform bovine milk protein, opening a new world where our nutrients can do more for us,” said Laura Katz, founder and chief executive officer of Helaina. “This exciting new discovery fosters our goal of developing a portfolio of advanced human bioactive proteins that address real health needs and new possibilities in nutrition science.”

In July 2023, Helaina won IFT FIRST’s pitch event, taking home a $10,000 grand prize for its human lactoferrin product. The human lactoferrin product is a bioactive compound that “regulates iron levels, improves nutrient absorption and improves cognitive health,” said Paola Delgado, chief operating officer.